Riociguat (Adempas, BAY63-2521) + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Scleroderma, Systemic
Conditions
Scleroderma, Systemic
Trial Timeline
Jan 15, 2015 → Mar 28, 2019
NCT ID
NCT02283762About Riociguat (Adempas, BAY63-2521) + Placebo
Riociguat (Adempas, BAY63-2521) + Placebo is a phase 2 stage product being developed by Bayer for Scleroderma, Systemic. The current trial status is completed. This product is registered under clinical trial identifier NCT02283762. Target conditions include Scleroderma, Systemic.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02283762 | Phase 2 | Completed |
| NCT02138825 | Phase 2 | Terminated |
| NCT01926847 | Phase 2 | Completed |
| NCT01065051 | Phase 2 | Terminated |
| NCT00855465 | Phase 3 | Completed |
Competing Products
15 competing products in Scleroderma, Systemic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IVA337 + Placebo | Inventiva | Phase 2 | 47 |
| Cuprimine (penicillamine) | Merck | Pre-clinical | 23 |
| rapcabtagene autoleucel + rituximab | Novartis | Phase 2 | 52 |
| STI571 | Novartis | Phase 2 | 52 |
| Imatinib mesylate | Novartis | Phase 2 | 52 |
| imatinib mesylate | Novartis | Phase 2 | 52 |
| Mycophenolate mofetil | Roche | Pre-clinical | 23 |
| Mycophenolate mofetil + Cyclophosphamide + Placebo | Roche | Phase 2 | 52 |
| Fludarabine + Cyclophosphamide + Thymoglobulin | Amgen | Phase 1 | 32 |
| BMS-986020 | Bristol Myers Squibb | Phase 2 | 51 |
| dasatinib | Bristol Myers Squibb | Phase 1/2 | 40 |
| Abatacept + Placebo | Bristol Myers Squibb | Phase 1/2 | 40 |
| AVID200 | Bristol Myers Squibb | Phase 1 | 32 |
| Rilonacept | Regeneron Pharmaceuticals | Phase 1/2 | 40 |
| Riociguat + Placebo | Bayer | Phase 2 | 49 |